These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30211701)

  • 1. Pegloticase-Associated Hemolysis.
    Minshar MA; Osman-Malik Y; Bhat ZY
    Am J Ther; 2019; 26(5):e622-e624. PubMed ID: 30211701
    [No Abstract]   [Full Text] [Related]  

  • 2. Methaemoglobinaemia and haemolysis following pegloticase infusion for refractory gout in a patient with a falsely negative glucose-6-phosphate dehydrogenase deficiency result.
    Geraldino-Pardilla L; Sung D; Xu JZ; Shirazi M; Hod EA; Francis RO
    Rheumatology (Oxford); 2014 Dec; 53(12):2310-1. PubMed ID: 25224415
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemolytic Anemia Induced by Pegloticase Infusion in a Patient With G6PD Deficiency.
    Owens RE; Swanson H; Twilla JD
    J Clin Rheumatol; 2016 Mar; 22(2):97-8. PubMed ID: 26906307
    [No Abstract]   [Full Text] [Related]  

  • 4. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
    Biggers K; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegloticase hypersensitivity desensitisation: an outpatient, 3-bag, 12-step protocol.
    Botson JK
    BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32565437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegloticase: withdrawal of its European marketing authorisation is welcome.
    Prescrire Int; 2017 Mar; 26(180):71. PubMed ID: 30730621
    [No Abstract]   [Full Text] [Related]  

  • 7. [Gout and other crystal-induced arthritides].
    Manger B
    Dtsch Med Wochenschr; 2012 Aug; 137(31-32):1579-81. PubMed ID: 22786675
    [No Abstract]   [Full Text] [Related]  

  • 8. Rasburicase-induced methaemoglobinaemia and G6PD deficiency in an unusual suspect.
    Oluwasanjo A; Alese O; Swierczynski S; Forman D
    Br J Haematol; 2015 Sep; 170(5):595. PubMed ID: 26033222
    [No Abstract]   [Full Text] [Related]  

  • 9. Pegloticase for treatment of tophaceous polyarticular gout.
    Seifried RM; Roberts J
    Hawaii J Med Public Health; 2013 Jul; 72(7):220-3. PubMed ID: 23901393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.
    Calabrese LH; Kavanaugh A; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2017 Aug; 19(1):191. PubMed ID: 28818095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
    Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
    J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A ghostly presence-G6PD deficiency.
    Bain BJ
    Am J Hematol; 2010 Apr; 85(4):271. PubMed ID: 20196170
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.
    Bleyer AJ; Wright D; Alcorn H
    Clin Nephrol; 2015 May; 83(5):286-92. PubMed ID: 25816806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
    Schlesinger N; Lipsky PE
    Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
    Becker MA; Baraf HS; Yood RA; Dillon A; Vázquez-Mellado J; Ottery FD; Khanna D; Sundy JS
    Ann Rheum Dis; 2013 Sep; 72(9):1469-74. PubMed ID: 23144450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyanosis in a male Nigerian infant with acute kidney injury: answers.
    Pansy J; Mache CJ; Zobel G; Grangl G; Ring E; Hoffmann KM
    Pediatr Nephrol; 2014 Jun; 29(6):1011-3. PubMed ID: 23989394
    [No Abstract]   [Full Text] [Related]  

  • 18. Brisk clinical response to erythrocytapheresis in a G6PD-deficient patient with rasburicase-induced methemoglobinemia.
    Cooling L
    J Clin Apher; 2017 Dec; 32(6):599-600. PubMed ID: 28370399
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
    Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Needle or Knife: Pegloticase for Refractory Crippling Gout in a Nonagenarian.
    Choi N; Eickhoff J; Keith M
    J Clin Rheumatol; 2017 Sep; 23(6):343. PubMed ID: 28816765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.